A Word On Why Current Patents Are Key To Koos Plan
What I'm about to say arises from my 30+ Years as a Clinical Trials M.D. Principal Investigator who interfaced with scores of Big Pharmas over the decades to bring their INDs to Market supported of course by my dedicated team of industry professionals.
Listen, Koos reactivating RGBP's Patents means this.
Big Pharmas have NO interest in EXPIRED Patents! Why???
#1- they are obviously not the developers of the Patent and all the years of science that went into it.
#2- typically expired Patents are NOT re-activated by an "acquiring" Big Pharma and here's the main reason why:
Upon attempting to re-activate an expired Patent for IND application, they are subject to the FDA asking a battery of questions that their science team may not be able to adequately address based on available new information since the Patent expired, AND/OR, the FDA may not have address relevant questions they needed to ask the first time BASED ON the current review board examiners who may know MORE than the previous ones. Is this making sense??
If that happens, and the acquiring Big Pharma isn't able to thoroughly address ALL the FDA's questions to their satisfaction, the Patent will NOT be reactivated and they will have flushed all the money they paid for the Patent down the toilet. Also, keep in mind that it takes only ONE (1) of the FDA Board Review members to NOT agree with re-activation which is adequate to kill the Patent for reason approval must be by unanimous Board Review Vote.
The above is scenario of buying an expired Patent as a rough comparison would be like buying a new Rolls-Royce with no engine or transmission! Who in their right mind would do that??
Big Pharmas acquiring Patents are ONLY interested in Current FDA Approved Patents that they can immediately put in their clinical trials pipeline! They definitely are NOT interested in having to address someone else's science that may require lengthy elaboration to the FDA that they may not be able to sufficiently address to their satisfaction. If if anything, it's simply NOT worth the RISK that the FDA may NOT approve the Patent for re-activation!
Koos knows this which is likely part of his motive of WHY he went to all the trouble to re-activate RGBP's Patents. This in and of itself speaks volumes of his possible intention to SELL the Company combined of course with him filing that 8K that protects against a Hostile Take Over! I'm not saying he will sell the Company BUT this definitely positions that to easily happen!
I hope this helps..
Be well and prosper...
